Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder (OCDDRUG)

Osaka City University

Status and phase: Completed; Phase 4

Conditions: SSRI-Refractory Obsessive-Compulsive Disorder

Treatments: Behavioral: exposure response prevention; Drug: atypical antipsychotic drug

Study type: Interventional

Funder types: Other

Identifiers

NCT00854919

18591305

Details and patient eligibility

About

Objective: Although atypical antipsychotic drugs (AAPDs) have been found effective in the augmentation of serotonin reuptake inhibitors (SRIs) for treatment-resistant obsessive-compulsive disorder (OCD) in short terms trials, there are few data on the effectiveness and safety of these agents in clinical settings over the long term.

Method: Subjects (n=46) who responded to selective SRIs (SSRIs) in an initial 12-week trial were continued on SRI-monotherapy plus cognitive-behavioral therapy (CBT) for one year. Subjects (n=44) who failed to respond to SSRIs were randomly assigned to one of 3 AAPDs such as risperidone and were consecutively treated using SSRI+AAPD combined with CBT for a year.

Full description

More recently, second-generation atypical antipsychotic drugs (AAPD) that modulate both 5-HT and DA function, such as risperidone (RIS), olanzapine (OLZ) and quetiapine (QET), have been found effective in the augmentation of SSRIs for treatment-resistant OCD.

Nevertheless, the AAPDs have been associated with common and serious adverse effects, such as body weight (BW) gain and metabolic dysregulation. Metabolic dysregulation includes glucoregulatory dysfunction and dyslipidemia. Indeed, studies of some AAPD in SSRI-refractory OCD patients have similarly reported significant BW gain. AAPD-induced BW gain may influence patients' adherence to medication and places them at risk for a broad range of medical problems.

Most work on AAPDs in treatment-refractory OCD has been conducted in the form of short-term efficacy studies. There have been fewer studies of the effectiveness, safety, and tolerability of these agents in the context of a clinic where CBT is also provided, and where treatment is continued for a significant period of time. In the current effectiveness study, we sought to examine the response of SSRI-refractory patients to augmentation with AAPDs, comparing adverse events in such compared to a control group of SSRI responders.

Sex: All

Ages: 20 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, 18 years of age or over
• Patients were diagnosed as having obsessive-compulsive disorder by the Structured Clinical Interview for DSM-IV Patient version (SCID-P)
• They received standardized treatment for at least 1 year at the OCD clinic in our university hospital.
• Each subject gave written informed consent to take part after receiving a complete description of this study.
• All subjects were free of medical illness based on results of physical examination and screening tests of blood and urine, and no subjects received any lipid lowering or hypoglycemic agent during the 1-year study period.

Exclusion criteria

• Current clinically significant medical conditions such as diabetes

Trial design

0 participants in 3 patient groups

CBT

Experimental group

Description:

All subjects received cognitive-behavioral therapy (CBT) during the study period.

Treatment:

Behavioral: exposure response prevention

1

Experimental group

Description:

Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration

Treatment:

Behavioral: exposure response prevention

Drug: atypical antipsychotic drug

2

Active Comparator group

Description:

Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.

Treatment:

Behavioral: exposure response prevention

Drug: atypical antipsychotic drug